weekly_roundup

BioTechSign Daily Catalyst Roundup - November 14, 2026

Top BioTechSign catalyst names today: EYPT, GRFS, NKTR, ARGX, NUVB, BBIO. FDA, clinical trial, grade-change, dilution, and sentiment signals.

BiotechSign AnalysisNovember 14, 2026

Daily Biotech Catalyst Digest: November 14, 2026

EYPT leads the current BioTechSign screen at 84.2/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.

Top Catalyst Scores

TickerCompanyScoreGradeStrongest Inputs
EYPTEyePoint, Inc.84.2Aclinical activity 100%, short interest 70%, dilution risk 43%
GRFSGrifols SA74.8Bpublication signal 100%, clinical activity 100%, dilution risk 19%
NKTRNektar Therapeutics74.4Bpublication signal 100%, short interest 90%, clinical activity 75%
ARGXargenx SE74.0Bpublication signal 100%, clinical activity 100%, dilution risk 15%
NUVBNuvation Bio73.6Bclinical activity 88%, PDUFA timing 75%, short interest 70%
BBIOBridgeBio Pharma73.2BPDUFA timing 100%, publication signal 100%, clinical activity 100%

Recent Grade-Change Queue

  • PBYI (Puma Biotechnology Inc) currently grades F with a 34.2/100 catalyst score. Main inputs: publication signal 100%, clinical activity 54%, short interest 50%.
  • NSRX (Nasus Pharma Ltd.) currently grades D with a 36.1/100 catalyst score. Main inputs: clinical activity 58%, dilution risk 45%, publication signal 20%.
  • SMMT (Summit Therapeutics Inc.) currently grades D with a 45.2/100 catalyst score. Main inputs: publication signal 100%, short interest 90%, dilution risk 25%.
  • QTTB (Q32 Bio Inc.) currently grades D with a 35.5/100 catalyst score. Main inputs: short interest 90%, dilution risk 48%, publication signal 35%.
  • KRYS (Krystal Biotech) currently grades F with a 34.1/100 catalyst score. Main inputs: publication signal 70%, clinical activity 58%, short interest 50%.
  • CRVS (Corvus Pharmaceuticals) currently grades D with a 37.9/100 catalyst score. Main inputs: publication signal 100%, short interest 70%, dilution risk 68%.
  • CUE (Cue Biopharma, Inc.) currently grades D with a 46.6/100 catalyst score. Main inputs: dilution risk 91%, short interest 70%, publication signal 65%.
  • INBX (Inhibrx Inc) currently grades C with a 56.5/100 catalyst score. Main inputs: publication signal 100%, short interest 90%, clinical activity 83%.

What To Watch

Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.